Research Scientist, Computational Science at Axsome Therapeutics Inc

San Diego, California, United States

Apply Now

$110,000 – $138,000Compensation

Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

PhD or equivalent degree in a computational field, or commensurate job experience
Skills: Python programming, statistics, drug discovery
Able to locate in San Diego

Responsibilities

Design, train, evaluate and deploy ML models for predicting drug-target interactions and molecular properties
Apply ML models to the prioritization of virtual molecules: including de novo design ideas, HTE libraries and commercial collections
Partner with computational chemists, medicinal chemists and biologists to leverage ML insights for decision-making
Serve as a bridge between the bench and our computational platforms
Translate scientific questions into computational workflows and deliver actionable results
Present results to project teams and senior leadership, explaining methods, implications and recommendations
Collaborate with ML group to optimize model performance and evolve platforms

Skills

Python

Machine Learning

Statistics

Cheminformatics

Molecular Modeling

Structure-based Drug Design

Drug Discovery

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free